Loading...
•
Mar 28
Danaher Q1 2025 Earnings Report
Danaher reported stable revenue and stronger-than-expected earnings and cash flow in Q1 2025.
Key Takeaways
Danaher’s Q1 2025 performance exceeded expectations, with net income reaching nearly $1 billion, flat core revenue, and continued strength in bioprocessing and diagnostics segments.
Net income was $954 million with diluted EPS of $1.32 and adjusted EPS of $1.88.
Revenue declined 1.0% year-over-year to $5.741 billion.
Free cash flow came in at $1.06 billion.
Core revenue remained flat compared to the same quarter last year.
Danaher
Danaher
Danaher Revenue by Segment
Revenue by Segment
Biotechnology Revenue
CapyFin.comLife Sciences Revenue
CapyFin.comDiagnostics Revenue
CapyFin.com Forward Guidance
Danaher expects low single-digit core revenue growth in Q2 2025 and maintains its full-year outlook with 3% core revenue growth and adjusted EPS between $7.60 and $7.75.
Positive Outlook
- Momentum continues in bioprocessing.
- Better-than-expected respiratory demand supports diagnostics.
- Danaher Business System (DBS) continues to drive productivity gains.
- Strong balance sheet supports resilience.
- Innovation and market share gains expected to continue.
Challenges Ahead
- Revenue remains flat YoY, with pressure in diagnostics and life sciences.
- Macroeconomic backdrop becoming more dynamic.
- Lower cash flow compared to the previous year.
- No geographic breakdown or growth detail provided.
- Continued headwinds in parts of the diagnostics segment.
Revenue & Expenses
Visualization of income flow from segment revenue to net income